Literature DB >> 23143815

Environmental allergies and respiratory morbidities in cystic fibrosis.

Joseph M Collaco1, Christopher B Morrow, Deanna M Green, Garry R Cutting, Peter J Mogayzel.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is characterized by recurrent respiratory infections and progressive lung disease. Although environmental factors account for 50% of the variation in CF lung function, few specific exposures have been identified. Studies using small study samples focusing on environmental allergies in CF have had inconsistent results. Our objective was to examine the role of environmental allergies in upper and lower respiratory tract morbidities in CF.
METHODS: A total of 1,321 subjects with CF were recruited through the U.S. CF Twin-Sibling Study. Questionnaires were used to determine the presence/absence of environmental allergies. Questionnaires, chart review, and U.S. CF Foundation Patient Registry data were used to track outcomes.
RESULTS: Within the study sample 14% reported environmental allergies. Environmental allergies were associated with a higher risk of sinus disease (adjusted OR: 2.68; P < 0.001) and nasal polyps (adjusted OR: 1.74; P = 0.003). Environmental allergies were also associated with a more rapid decline in lung function (additional -1.1%/year; P = 0.001). However, allergies were associated with a later median age of acquisition of Pseudomonas aeruginosa (6.6 years vs. 4.4 years; log rank P = 0.027). The reported use of common allergy medications, anti-histamines and leukotriene inhibitors, did not alter the frequency of respiratory morbidities.
CONCLUSIONS: Environmental allergies are associated with an increased risk of sinus disease and nasal polyps and a more rapid decline in CF lung function, but may have a protective effect against the acquisition of P. aeruginosa. Prospective studies are needed to confirm these associations which have implications for more aggressive management of allergies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  FEV1; Pseudomonas aeruginosa; allergies; cystic fibrosis; lung function; nasal polyps; sinus disease

Mesh:

Year:  2012        PMID: 23143815      PMCID: PMC3572264          DOI: 10.1002/ppul.22700

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  44 in total

1.  Questionnaire predictors of atopy in a US population sample: findings from the National Health and Nutrition Examination Survey, 2005-2006.

Authors:  Jane A Hoppin; Renee Jaramillo; Paivi Salo; Dale P Sandler; Stephanie J London; Darryl C Zeldin
Journal:  Am J Epidemiol       Date:  2011-01-27       Impact factor: 4.897

2.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.

Authors:  J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting
Journal:  J Pediatr       Date:  2010-06-30       Impact factor: 4.406

Review 3.  Rhinitis and sinusitis.

Authors:  Mark S Dykewicz; Daniel L Hamilos
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

4.  [Association of TGFB1 gene polymorphism -509C/T with disease severity in childhood allergic rhinitis].

Authors:  Xin-jie Zhu; Lu-ping Zhu; Mei-ping Lu; Mei-lin Wang; Qin-hong Qi; Min Yin; Zheng-dong Zhang; Lei Cheng
Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2010-06

Review 5.  Modifier genes in Mendelian disorders: the example of cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Ann N Y Acad Sci       Date:  2010-12       Impact factor: 5.691

Review 6.  Nasal polyposis and cystic fibrosis(CF): review of the literature.

Authors:  M N Feuillet-Fieux; G Lenoir; I Sermet; C Elie; J Djadi-Prat; M Ferrec; M Magen; V Couloigner; Y Manach; B Lacour; J P Bonnefont
Journal:  Rhinology       Date:  2011-08       Impact factor: 3.681

7.  Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001--2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-05-06       Impact factor: 17.586

8.  Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.

Authors:  Deanna M Green; Kathryn E McDougal; Scott M Blackman; Patrick R Sosnay; Lindsay B Henderson; Kathleen M Naughton; J Michael Collaco; Garry R Cutting
Journal:  Respir Res       Date:  2010-10-08

Review 9.  The 2007 GOLD Guidelines: a comprehensive care framework.

Authors:  Philip M Gold
Journal:  Respir Care       Date:  2009-08       Impact factor: 2.258

10.  Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study.

Authors:  Joseph M Collaco; John McGready; Deanna M Green; Kathleen M Naughton; Christopher P Watson; Timothy Shields; Scott C Bell; Claire E Wainwright; Garry R Cutting
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

View more
  4 in total

1.  Cat and dog exposure and respiratory morbidities in cystic fibrosis.

Authors:  Christopher B Morrow; Karen S Raraigh; Deanna M Green; Scott M Blackman; Garry R Cutting; Joseph M Collaco
Journal:  J Pediatr       Date:  2014-07-12       Impact factor: 4.406

2.  Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.

Authors:  Weili Li; David Soave; Melissa R Miller; Katherine Keenan; Fan Lin; Jiafen Gong; Theodore Chiang; Anne L Stephenson; Peter Durie; Johanna Rommens; Lei Sun; Lisa J Strug
Journal:  Hum Genet       Date:  2013-09-22       Impact factor: 4.132

Review 3.  European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre.

Authors:  Steven Conway; Ian M Balfour-Lynn; Karleen De Rijcke; Pavel Drevinek; Juliet Foweraker; Trudy Havermans; Harry Heijerman; Louise Lannefors; Anders Lindblad; Milan Macek; Sue Madge; Maeve Moran; Lisa Morrison; Alison Morton; Jacquelien Noordhoek; Dorota Sands; Anneke Vertommen; Daniel Peckham
Journal:  J Cyst Fibros       Date:  2014-05       Impact factor: 5.482

Review 4.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.